e20505 Background: End-of-life chemotherapy (EOLC) use in metastatic breast cancer (MBC) is poorly described. We aimed to estimate the prevalence and identify the predictors of EOLC in MBC. Methods: We conducted a single institution retrospective chart review of women with MBC who died between 1/1/10 and 9/30/14. Demographic information, tumor characteristics, and survival were obtained. Dates of last chemotherapy administration were confirmed through patient charts. EOLC use was defined as receipt of chemotherapy within 4 weeks of death. The non-end-of-life chemotherapy group (non-EOLC) included all patients who did not belong to the EOLC category. Bivariate associations between multiple clinical characteristics and EOLC were tested for statistical significance using chi-square/Fisher’s exact or Wilcoxon Rank sum tests. Significant predictors for EOLC vs. non-EOLC were determined using a logistic regression model. p-values ≤ 0.025 were considered statistically significant. Results: 274 patients with MBC ...